SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing heightened volatility as investors debate the impact of a new partnership with Associated Carrier Group against broader macro-driven selling pressure. The community is actively tracking a potential short squeeze, citing high short interest and anticipation for upcoming earnings, while remaining divided between long-term bullish outlooks on voice AI adoption and frustration over recent stock dilution.

Operates as a holding company with interest in providing social shopping platform solutions

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop Holdings is seeing intense retail speculation and extreme volatility as traders draw parallels between its micro-float setup and previous short squeeze rallies. While the community is actively debating the sustainability of its business model, the stock continues to experience frequent trading halts and heavy momentum-driven volume.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is experiencing heightened market volatility as it navigates a classic 'sell the news' reaction to stellar earnings that blew past analyst expectations, alongside ongoing community concerns regarding Middle East supply chain risks. While investors remain bullish on the long-term AI supercycle driving the company's record-breaking margin expansion, the stock is currently subject to intense debate over whether current valuations are sustainable given geopolitical headwinds.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is experiencing a significant surge in momentum driven by a combination of key technical breakthroughs, such as successful photonic interconnect testing, and a major contract win with DARPA. The community is actively debating the stock's potential for a massive short squeeze, drawing comparisons to past high-growth sector rotations, while also closely watching for potential dilution and the long-term viability of the company's quantum platform.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is surging as the community reacts to a record production order from a major hyperscale AI customer, which has fueled intense debate between bulls banking on the company's long-term role in AI infrastructure and skeptics pointing to heavy insider selling and recent share offerings. Traders are actively discussing the stock's parabolic climb, with many debating whether the current momentum represents a sustainable breakout in the semiconductor testing market or an overextended bubble primed for a sharp correction.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of therapeutics for chronic liver diseases and viral infections. The firm is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses, as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). The company was founded by Lucinda Quan and Lawrence M. Blatt on February 5, 2018 and is headquartered in South San Francisco, CA.

Aligos Therapeutics Inc

Aligos Therapeutics is seeing active community debate as investors weigh the potential of its MASH and HBV pipeline against the company's capital needs. Despite significant volatility and concerns over future funding, many traders are closely tracking upcoming interim data and potential partnership catalysts that could significantly impact the stock's valuation.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending as investors bet on a potential short squeeze fueled by record short interest and significant backing from Tether, while anticipation builds around the pending Northern Data acquisition and the company's expansion into AI cloud services.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies has surged in trading volume following its recent transition to a publicly listed entity, with the community actively debating the potential for a short squeeze driven by its low float and high borrow costs. While bulls are excited by the company's partnerships with major tech and aerospace firms, skeptics are expressing concerns over high cash burn and the speculative nature of its quantum computing milestones.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, sentiment-driven rally fueled by high short interest and retail momentum, prompting intense debate between traders banking on further squeeze potential and those expecting a swift collapse to fundamental valuations. Community members are actively tracking share dilution efforts and historical volatility patterns, with many debating whether the stock will mirror past parabolic blow-off tops or continue its aggressive upward trajectory.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is rallying as investors express growing confidence in its member growth and fintech product ecosystem, fueling chatter about a potential short squeeze as the stock reclaims key technical levels. The community is actively debating the stock's long-term potential compared to peers like Robinhood, while sentiment turns increasingly bullish heading into the upcoming earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +0.98% and -91.09%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q3 Loss, Lags Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -8.66% and -94.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART (VXRT) delivered earnings and revenue surprises of +22.22% and +1,206.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

The Beauty Health Company (SKIN) Surpasses Q2 Earnings and Revenue Estimates

Beauty Health (SKIN) delivered earnings and revenue surprises of +150.00% and +4.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Select Medical (SEM) Surpasses Q2 Earnings and Revenue Estimates

Select Medical (SEM) delivered earnings and revenue surprises of +14.29% and +1.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Biotechs have underperformed the broader market this year, and these stock are at crossroads as they await the new administration under Donald Trump to take over shortly after the new year.The SPDR S&amp;P Biotech ETF ($XBI) has gained 9.2% for the year-to-date period compared to the 25%+ gain for the S&amp;P 500 Index. The iShares Biotechnology ETF ($IBB), which has a relatively higher proportion of mid- and large-cap stocks, has also added under 10% so far this year.The underperformance takes away the sheen of the industry’s defensive credentials.&nbsp;R&amp;D momentum slowed during the year, as is evident from the new molecular entity approvals, which number 38 so far this year compared to 47 for the same period last year.&nbsp;&nbsp;Most biotech companies operate deep in the red for a very long time until they could begin commercializing products. They rely on debt financing which came to be expensive in an elevated interest rate environment.&nbsp;With a change of guard on the political arena following Trump's win, the outlook for the industry is yet unclear.Morgan Stanley Head of Policy Monica Guerra&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.morganstanley.com/articles/trump-re-election-implications-for-markets">said&nbsp;</a>in a recent note that deregulation is likely to be a major theme expected during the second term. “Less stringent requirements in pharmaceuticals and biotechnology, meanwhile, could help those industries by prompting accelerated drug approvals,” she said.BMO Capital Markets analyst Evan Seigerman said the election results are “modestly positive” for the biopharma sector,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fiercepharma.com/pharma/trump-white-house-again-whats-ahead-pharma">according</a> to FiercePharma. The analyst sees potential deprioritization of the Internal Revenue Service, likely less Federal Trade Commission interference, and lower corporate taxes.Jefferies analysts does not expect the proposed drug pricing reforms to pass as the Republican legislators are divided over the proposals.Amid the ongoing discussions about the implications of Trump’s presidency, here’s a few biopharma stocks that are on retail’s radar (based on the number of followers on the Stocktwits platform):Moderna, Inc. ($ MRNA): 107,109 watchersNovavax, Inc. ($NVAX): 101,846Pfizer, Inc. ($PFE): 99,425 watchersiBio, Inc. ($IBIO): 93,617 watchersInovia Pharma, Inc. ($INO): 93,414 watchersJaguar Health ($JAGX): 81,859 watchersGilead Sciences, Inc. ($GILD): 77,094 watchersVaxart, Inc. ($VXRT): 75,807 watchersTonix Pharmaceutical Holding Corp. ($TNXP): 72,666 watchersSorrento Therapeutics, Inc. ($SRNE): 68,474 watchersRead Next:&nbsp; <a href="https://stocktwits.com/news-articles/markets/equity/block-ceo-jack-dorsey-weighs-in-on-election-impact/cJ4EMJ3Raj">Block CEO Jack Dorsey Keeps Fingers Crossed Over Regulatory Environment As Trump Makes A Comeback</a>For updates and corrections email newsroom@stocktwits.com&nbsp;

GOP lawmakers are divided over drug pricing reforms.

Will Trump 2.0 Nurse Biotechs Back To Health: 10 Stocks Retail Is Watching

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.

Equity

Less stringent requirements in pharmaceuticals and biotechnology could help by prompting accelerated drug approvals.


Vaxart Inc

Registration filing

Vaxart, Inc. is a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded by Sean Tucker in March 2004 and is headquartered in South San Francisco, CA.

VXRT
Vaxart Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VXRT News

VXRTVaxart Inc